Between 4.5 and 8 months , NVAS compared with placebo was associated with higher mortality in early MV recipients ( MR = 30 versus MR = 0 , p = 0.01 ) , but not in children who did not receive early MV ( p for interaction between NVAS and early MV = 0.03 ) .